RUDRA Registry (Real-World Clinical Registry for Patients With Recurrent Pericarditis)

А multicenter, non-interventional real world clinical registry of patients with recurrent pericarditis.

The main goal of the registry is to epidemiologically assess the pattern, clinical outcomes, and approaches to therapy in patients with recurrent pericarditis.

This goal can best be achieved through a registry of real clinical practice. Epidemiologic assessment of the structure will be possible due to the retrospective part of the registry and will give an idea of the etiology of RP in the Russian Federation, as well as allow to identify a subpopulation of patients with idiopathic recurrent pericarditis and study it in more detail. The prospective branch involves three-year dynamic follow-up of patients with already diagnosed and newly diagnosed IRP. Based on the data obtained during the retro- and prospective parts of the registry, it will be possible to evaluate clinical outcomes and approaches to therapy in patients with recurrent pericarditis, which may become valuable material for assessing the real clinical situation in the Russian Federation, as well as deepen knowledge on the diagnosis and management of this cohort of patients.

Inclusion criteria

• Men or women 18 years of age or older at the time of data recording or pericarditis debut;
• Presence of one of the following conditions:

• a specialist-confirmed diagnosis of recurrent pericarditis without an established etiology at the time of inclusion in the study (suspected "idiopathic recurrent pericarditis");
• a specialist-confirmed diagnosis of "idiopathic recurrent pericarditis".

Exclusion criteria

• Age below 18 years at the time of inclusion in the registry or debut of pericarditis;
• Specialist-confirmed secondary genesis of RP (infectious, autoimmune, neoplastic, metabolic, traumatic, iatrogenic, etc.); 2. Manifestations and complications of myocarditis, various diseases of thoracic organs, systemic diseases, cardiac surgery, radiation therapy, tuberculosis, etc.);
• lack of possibility of screening examination and dynamic follow-up;
• Organ/tissue transplantation less than 5 years prior to study inclusion or debut of pericarditis;
• Oncologic disease less than 3 years prior to study inclusion or pericarditis debut;
• Chemotherapy with anthracycline-type drugs at the time of pericarditis debut;
• Administration of amphetamine-type drugs at the time of pericarditis debut;
• Cardiac/pericardial surgery in the last 6 months prior to study inclusion or pericarditis debut;
• Myocardial infarction in the last 3 months prior to study inclusion or debut of pericarditis;
• Traumatic chest injury in the last 3 months prior to study inclusion or pericarditis debut;
• Absence of an informed consent form signed by the patient for participation in the study